Ther Adv Med Oncol 2013, 5:105–118.PubMedCrossRef 12. Culos KA, Cuellar S: Novel targets in the treatment of advanced melanoma: New first-line treatment options (april). Ann Pharmacother 2013,47(4):519–526.PubMedCrossRef 13. Hatzivassiliou G, Song K, Yen I, Brandhuber selleck inhibitor BJ, Anderson DJ, Alvarado R, Wortmannin solubility dmso Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al.: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431–435.PubMedCrossRef 14. Heidorn

SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209–221.PubMedCrossRef 15. Fremin C, Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010, 3:8.PubMedCrossRef

16. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD: Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin find more Cancer Res 2010, 16:1924–1937.PubMedCrossRef 17. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, et al.: Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009, 11:720–731.PubMed 18. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al.: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107–114.PubMedCrossRef 19. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D: MEK and the inhibitors: from bench to bedside. J

Hematol Oncol 2013, 6:27.PubMedCrossRef 20. Frank NY, Schatton T, Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010, 120:41–50.PubMedCrossRef 21. Smalley KS, Herlyn M: Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int J Cancer 2009, 124:1245–1250.PubMedCrossRef 22. Ma J, Frank MH: Tumor initiation in human malignant melanoma and potential cancer therapies. Tyrosine-protein kinase BLK Anticancer Agents Med Chem 2010, 10:131–136.PubMedCrossRef 23. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S: Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Experimental Clin Cancer Res : CR 2013, 32:48.CrossRef 24. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328–9337.PubMedCrossRef 25.